Litcius/Paper detail

Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy

Y. Tsang, Hannah Tharmalingam, Katherine Belessiotis-Richards, S. Armstrong, Peter Ostler, Robert Hughes, Roberto Alonzi, Peter Hoskin

2021Radiotherapy and Oncology23 citationsDOI

Topics & Concepts

SABR volatility modelMedicineBrachytherapyProstate cancerNuclear medicineCumulative incidenceRadiation therapyAblative caseUrologyPopulationCumulative doseGenitourinary systemIncidence (geometry)CancerRadiologyInternal medicineCohortStochastic volatilityOpticsEnvironmental healthVolatility (finance)PhysicsEconomicsFinancial economicsProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and ResearchAdvanced Radiotherapy Techniques
Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy | Litcius